GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyeGene Inc (XKRX:185490) » Definitions » Cyclically Adjusted Price-to-FCF

EyeGene (XKRX:185490) Cyclically Adjusted Price-to-FCF : (As of Jan. 18, 2025)


View and export this data going back to 2015. Start your Free Trial

What is EyeGene Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


EyeGene Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for EyeGene's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyeGene Cyclically Adjusted Price-to-FCF Chart

EyeGene Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

EyeGene Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of EyeGene's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, EyeGene's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EyeGene's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyeGene's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where EyeGene's Cyclically Adjusted Price-to-FCF falls into.



EyeGene Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

EyeGene's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, EyeGene's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-81.724/*
=

Current CPI (Sep. 2024) = .

EyeGene Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.000 99.098 0.000
201503 -107.422 99.720 0.000
201506 -35.982 100.050 0.000
201509 -139.047 100.110 0.000
201512 -117.152 100.220 0.000
201603 -99.009 100.560 0.000
201606 -112.505 100.790 0.000
201609 -161.544 101.460 0.000
201612 -195.872 101.560 0.000
201703 -95.741 102.850 0.000
201706 -153.892 102.610 0.000
201709 -125.058 103.490 0.000
201712 -156.758 102.990 0.000
201803 -62.485 104.100 0.000
201806 -147.380 104.130 0.000
201809 -333.310 105.650 0.000
201812 -177.658 104.350 0.000
201903 -114.535 104.490 0.000
201906 -184.956 104.880 0.000
201909 -200.304 105.200 0.000
201912 -159.509 105.120 0.000
202003 -210.792 105.540 0.000
202006 -125.227 104.870 0.000
202009 -186.087 106.200 0.000
202012 -199.560 105.765 0.000
202103 -193.839 107.357 0.000
202106 -218.191 107.579 0.000
202109 -1,797.493 108.759 0.000
202112 -562.472 109.676 0.000
202203 -354.518 111.806 0.000
202206 -194.409 114.083 0.000
202209 -195.229 114.831 0.000
202212 -163.944 115.200 0.000
202303 -282.639 116.550 0.000
202306 -328.362 117.140 0.000
202309 -196.815 119.111 0.000
202312 -197.833 118.848 0.000
202403 -226.533 118.848 0.000
202406 -256.612 0.000
202409 -81.724 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


EyeGene  (XKRX:185490) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


EyeGene Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of EyeGene's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


EyeGene Business Description

Industry
Traded in Other Exchanges
N/A
Address
Gangseo-gu, Seoul 401, B-dong 910 Gayang-dong, Seoul, KOR, 07528
EyeGene Inc is a South Korea based bio-venture company. It researches and develops biopharmaceuticals. Its products include EG-Mirotin, EG-HPV, EGVac systems. It provides drugs for the treatment of age-related degenerative diseases. Its products target diabetic retinopathy.

EyeGene Headlines

No Headlines